Predictors of Intracranial Atherosclerotic Disease in Posterior Circulation: a Cohort Study
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSohag University
About this trial
Early identification of intracranial atherosclerotic disease (ICAD) may impact the management of patients undergoing mechanical thrombectomy (MT). The aim of the study is to develop and validate a scoring system for pre-thrombectomy diagnosis of ICAD in posterior circulation large vessel/distal medium vessel occlusion strokes (LVOs/DMVOs).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult ≥18 years
Patient with posterior circulation strokes who underwent mechanical thrombectomy.
Disqualifiers
Patients with anterior circulation stroke.
Patients with intracranial hemorrhage
Patients without baseline radiological data.
Extracranial large vessel atherosclerosis related strokes.
Trial population
The cohort is divided into 2 groups; 1. ICAD-related stroke made when a smooth-bordered lesions leading to delayed perfusion on conventional-angiography (without competing stroke etiology) or when irregular-surfaced lesions involving the target vessel during mechanical thrombectomy were unveiled (with or without competing stroke etiology). 2. Non-ICAD cases (controls) includes patients with posterior circulation stroke attributed to stroke etiologies other than ICAD.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
we are aiming to develop a Scoring system based on certain variables derived from both groups
Other interventionWe are aiming to develop a Scoring system based on certain variables derived from both group
Treatment groups
150 Participants
are divided into 2 treatment groupsGroup A: ICAD group1 intervention
Group B: Non-ICAD cases (controls)1 intervention
Trial outcomes
Primary outcomes
1
Post-procedural outcomes included any intracranial hemorrhage, symptomatic ICH (sICH)
sICH is defined as local or remote parenchymal hemorrhage type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline or leading to death that the physician judged was causative of the deterioration) per ECASS III criteria
Time frame
June 1st, 2025Secondary outcomes
1
90 day modified Rankin scale (mRS)
a score of 0 to 4 on the modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 4 moderately severe disability, and 6 death) at 90 days, was changed to a good functional status (a modified Rankin scale score of 0 to 3, with a score of 3 indicating moderate disability)
Time frame
June 1st, 20252
90 day mortality
Time frame
June 1st, 2025Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Sohag University
Lead sponsor
Emory University
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: